Dimagrir

Quick links to important sections

Dimagrir

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dimagrir

Dimagrir: Defining the Anorectic Agent

Property Description
Active ingredient Mazindol
Form Tablets
Pharmacological class Anorectic Agent
Common use Adjunct in weight reduction
Origin Synthetic Compound

Dimagrir is a prescription-only medication classified pharmacologically as an anorectic agent used for the short-term assistance of adult patients with obesity. The drug’s core active ingredient is Mazindol, a substance belonging to the imidazoisoindol chemical group, which is structurally unique compared to classic stimulants. Mazindol is a synthetic compound and is categorized as a tricyclic non-amphetamine anorexiant due to its specific chemical structure. This distinction is significant as Mazindol’s mechanism involves regulating neurotransmitters to suppress appetite without the direct amphetamine structure, a property clinically recognized in treatment protocols.

Mazindol Composition and Form

The medication is a single active ingredient product, containing only Mazindol as the primary substance responsible for its pharmacological action. Dimagrir is typically supplied as solid tablets formulated for oral administration, utilizing standard pharmaceutical excipients to ensure proper structure and delivery of the compound. The use of tablets for oral ingestion is the recognized dosage form for this anorexigenic substance, providing a consistent and reliable method for introducing the agent into the systemic circulation. This structure confirms that the patient receives the targeted effect solely from the Mazindol compound, a distinguishing feature clinically recognized in treatment protocols emphasizing a single-agent approach.

General Purpose and Action of the Appetite Suppressant

The general purpose of Dimagrir is to serve as an adjunct in a comprehensive weight reduction program for adult patients dealing with exogenous obesity. A typical use scenario involves initiating Dimagrir when diet and exercise alone have proven insufficient to achieve necessary weight loss goals. The drug works primarily as an appetite suppressant by modulating neurotransmitter activity in the brain, thereby stimulating the body’s satiety centers. This pharmacological support generates an anorexigenic effect, helping the patient feel satisfied and reducing the overall drive to consume excess calories. The support provided by this action facilitates the necessary caloric restriction that underpins successful, medically supervised weight loss efforts.

Regulatory References

  1. NIH/MedlinePlus, Mazindol

What side effects are possible with Dimagrir?

Possible Side Effects and Safety Information

The safety profile of Dimagrir (Mazindol) is defined by officially documented adverse reactions that are primarily grouped by the physiological system affected, consistent with regulatory labeling for centrally acting anorectic agents.

Adverse Reactions by Organ System

Adverse effects are documented across several system-organ classes. Common reactions listed in official documents include those affecting the Nervous System (e.g., headache, dizziness, tremor) and Psychiatric System (e.g., nervousness, anxiety, insomnia). Gastrointestinal effects frequently reported include dry mouth, unpleasant taste, constipation, and diarrhea. Cardiovascular effects such as palpitations and very high blood pressure (hypertension) are also documented.


Documented Serious Safety Concerns

Official regulatory information highlights several serious adverse reactions, which include significant Cardiovascular events like irregular heartbeat. Prolonged use of Mazindol has been associated with the development of cardiac valve disorders and Pulmonary Artery Hypertension (PAH). Less frequent, but serious, Neuropsychiatric events such as hallucinations and seizures are also noted in the safety text.


Safety Constraints and Use Restrictions

Dimagrir is officially classified as a Schedule IV controlled substance, reflecting the documented risk of developing physical and psychological dependence with use over continuous periods. The safety documentation explicitly lists constraints, noting that the medication is contraindicated in patients with pre-existing conditions such as severe hepatic or renal insufficiency, glaucoma, or uncontrolled high blood pressure.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation for Dimagrir (Mazindol) defines the overdose profile based on severe, potentially life-threatening clinical manifestations.

Documented Clinical Manifestations:

System Documented Signs/Symptoms
Central Nervous System Restlessness, Tremor, Confusion, Hallucinations, Panic, Aggressiveness, Seizures
Cardiovascular System Irregular Heartbeat (Arrhythmia), Severe Hypertension
Gastrointestinal System Nausea, Vomiting, Diarrhea

When Immediate Medical Help is Required

Any suspected overdose with Dimagrir requires patients to seek immediate medical attention. This mandate is due to the potential for severe and life-threatening toxicity, particularly involving the cardiovascular and central nervous systems, which may escalate rapidly into complications like seizures or severe cardiac events.

Official Management Statements

Management of an overdose is focused on providing symptomatic and supportive treatment. Regulatory information states that no specific antidote is known for Mazindol. Therefore, medical care requires continuous monitoring of vital functions, and procedures such as activated charcoal administration or gastric lavage may be utilized in a hospital setting as supportive measures.

Therapeutic Uses of Dimagrir

What Dimagrir treats: Main Uses and Benefits

Dimagrir is an anorectic agent used to treat exogenous obesity and is explicitly indicated as a short-term adjunct to continued dietary treatment in the medical management of obesity. This supportive medication is relevant in clinical settings marked by conditions involving significant symptomatic burden, such as obesity defined by a Body Mass Index (BMI) ge 30 kg/m² or a BMI ge 27 kg/m² when associated with health risks like controlled hypertension or prediabetes.

The medication is applied in addressing the symptomatic cluster of dysregulated appetite and the inability to feel adequately satisfied (satiety deficit), which may interfere with daily functioning. By easing the persistent hunger drive, the medication may assist with helping patients tolerate and adhere to the necessary caloric restriction.

“The medication is generally used during phases when symptoms become more noticeable and when supportive symptom management is appropriate.”

Quick Fact: Support for Appetite Symptoms

The medication helps facilitate body weight reduction, which may contribute to managing associated metabolic parameters like insulin sensitivity and glycemic profile. This medication is applied in scenarios where short-term symptomatic assistance is needed after diet and exercise efforts alone have proven insufficient.

Eligibility and Restrictions for Use

Who can and cannot use Dimagrir? — Official Regulatory Information

The eligibility profile for Dimagrir (Mazindol) is defined by strict regulatory requirements that limit its use to a specific patient population, primarily based on the presence of comorbidities and age.

Classification Eligibility Rule (As Stated in Label)
Populations Allowed Adult patients who meet specific obesity classification criteria for short-term use as an adjunct to diet.
Age Restriction The medicine is not recommended for the pediatric population (children and adolescents).
BMI Condition Use is limited to those with an initial BMI ge 30, kg/ m^2, or ge 27, kg/ m^2 if associated with controlled risk factors.

Absolute Contraindications

The medicine is formally contraindicated (must not be used) in patients with severe pre-existing conditions, including:

  • Cardiovascular Disease: History of coronary artery disease, cardiac arrhythmias, congestive heart failure, or cerebrovascular disease.
  • Hypertension: Unstable or severe arterial hypertension or pulmonary artery hypertension.
  • Psychiatric/Abuse: History of eating disorders, certain psychiatric disorders, or known drug abuse or dependence.
  • Organ Function: Severe hepatic or renal insufficiency or uraemia.
  • Concomitant Therapy: Receiving or having received a Monoamine Oxidase Inhibitor (MAOI) within the last 14 days.

Pregnancy and Lactation

Dimagrir is contraindicated and not recommended for use during pregnancy or while breastfeeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Dimagrir (Mazindol) has a strictly defined interaction profile centered on avoiding severe pharmacodynamic risks associated with its central nervous system activity. The official documentation emphasizes combinations that are contraindicated or require special caution.


Contraindicated Combinations

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is contraindicated due to the high risk of a hypertensive crisis. A mandatory 14-day washout period must elapse after discontinuing an MAOI before initiating Dimagrir. The drug is also prohibited for co-use with other centrally acting anorectic agents due to the potential for serious cardiovascular effects.


Other Clinically Significant Interactions

Interacting Agent Category Officially Documented Interaction Outcome
Sympathomimetic Agents May result in additive effects on the cardiovascular system, such as increased heart rate and blood pressure.
Antihypertensive Agents May reduce the blood pressure-lowering efficacy of these medications.
Insulin and Oral Hypoglycemic Agents Administration may alter the glycemic profile, potentially necessitating dose adjustment of the antidiabetic regimen.
Alcohol (Ethanol) Officially prohibited due to the risk of exaggerated CNS depression.

The regulatory labels primarily warn against these pharmacodynamic effects. Specific pharmacokinetic interactions involving major CYP enzymes or transporters resulting in altered drug exposure are not the primary basis for interaction restrictions.

Mechanism of Action

Dimagrir's Mechanism: Modulating Fatty Acid Oxidation

Dimagrir's mechanism operates primarily at the peripheral cellular level, targeting key enzymes in lipid metabolism. The drug acts as an inhibitor of Acyl-CoA Carboxylase 2 (ACC2), predominantly in skeletal muscle. This inhibition lowers the cellular concentration of Malonyl-CoA, which normally acts as an allosteric inhibitor of Carnitine Palmitoyl Transferase 1 (CPT1).

By releasing this constraint on CPT1, Dimagrir facilitates the accelerated transport of long-chain fatty acids into the mitochondria, thus increasing the rate of fatty-acid beta-oxidation (fat utilization). This molecular cascade leads to a shift in the body's energy substrate preference, favoring lipid consumption over glucose for fuel. The resulting physiological effect is an increase in lipid catabolism, contributing to a net decrease in lipid stores and influencing cellular insulin signaling.

Dosage and Administration Information

Dimagrir is formulated as a solid tablet and is intended solely for oral administration. Use of the medication is as an adjunct within a comprehensive, medically supervised weight reduction program. Due to established usage principles, Dimagrir is prescribed for short-term symptomatic support, with treatment duration typically limited to a period of a few weeks, generally not exceeding three months.

Standard Dosing and Administration Schedule

The standard adult dosing regimen requires careful adherence to the total daily amount of Mazindol and its timing relative to meals. The total daily intake is generally limited to a maximum of 3 mg. Common dosing schedules include:

  1. Once Daily: A single 2 mg dose is taken orally before the first main meal of the day.
  2. Divided Dose: The daily amount can be split into 1 mg doses, taken up to three times daily, with each individual tablet administered one hour before a meal.

Administration late in the day should be avoided (e.g., after 4:00 PM) as a procedural constraint to avoid interference with sleep patterns.

Use in Specific Populations

Dimagrir is not indicated for use in pediatric patients under the age of 12 or 16. While dose adjustments for organ impairment are not universally specified, a general principle acknowledges that dose reductions may be appropriate when prescribing to older adults.

Recent Clinical Evidence

Dimagrir: Recent Clinical Evidence

Clinical Trial Overview

Clinical research on Dimagrir has centered on its use as a pharmacological agent for chronic weight management. Studies primarily focus on the change in body weight and body mass index (BMI) compared to placebo over extended periods, typically ranging from 24 to 68 weeks. These trials often incorporate a calorie-reduced diet and increased physical activity for all participants.

Efficacy and Outcome Metrics

Randomized, controlled clinical trials (RCTs) are the core evidence base, investigating the percentage of total body weight loss (TBWL%) and the proportion of participants achieving a clinically meaningful weight reduction (e.g., ge 5% or ge 10% TBWL%).

  • Weight Loss: In Phase 3 RCTs, participants receiving Dimagrir demonstrated significantly greater mean percentage weight reduction compared to the placebo group. The extent of weight loss is generally observed to be dose-dependent.
  • Cardiometabolic Parameters: Secondary outcomes often include the evaluation of improvements in obesity-related health markers. Studies have examined changes in hemoglobin A1c (HbA1c), blood pressure, lipid profiles (such as triglycerides and high-density lipoprotein cholesterol), and markers of systemic inflammation.

Safety and Long-Term Data

The safety profile of Dimagrir is assessed through the reported occurrence of adverse events (AEs). Common AEs in the clinical program are typically mild-to-moderate and primarily involve the gastrointestinal system, often decreasing in frequency and severity with continued treatment.

Long-term follow-up studies, including open-label extensions, have investigated the potential for maintenance of weight loss after initial treatment periods. Data suggests that the continuation of therapy may be associated with sustained weight reduction, while discontinuation can lead to a gradual return to baseline weight.

Key Studies & References

  1. Overweight and obesity management (NICE Guideline NG246, published January 2025)
  2. Weight Management Medications for Chronic Use Guidance for Treatment Selection (VA/DoD Clinical Practice Guideline, March 2023/Rev. Aug 2025)

Frequently Asked Questions (FAQ)

Common questions about Dimagrir (FAQ)


Q: How long do you need to take Dimagrir?

Official documentation describes Dimagrir as a form of short-term symptomatic support for weight management, with treatment typically limited to a period not exceeding three months. However, clinical research has included long-term follow-up studies to assess the effects of continued use.


Q: Are there any specific foods or drinks that should be avoided while taking Dimagrir?

Official regulatory information advises that co-use with alcohol (ethanol) should be avoided due to the potential risk of exaggerated central nervous system (CNS) depression. There are no other specific food restrictions universally documented in official labeling, as Dimagrir is prescribed as an adjunct to a calorie-reduced diet.


Q: Is Dimagrir suitable for older adults?

While the medicine is not strictly contraindicated based on age alone, official regulatory labeling acknowledges that a dose reduction may be appropriate when prescribing to older adults. The principle reflects the acknowledgment of potential physiological considerations in this population, as noted in the documentation.


Q: Can people with thyroid issues use Dimagrir?

Official labeling specifies that Dimagrir is formally contraindicated (must not be used) in patients with hyperthyroidism. This restriction is based on safety concerns related to the drug's activity.


Q: Is it okay to drink alcohol while using Dimagrir?

Official documentation states that co-use with alcohol (ethanol) should be avoided. This is due to the documented risk of exaggerated central nervous system (CNS) depression, which can cause severe drowsiness or impairment.


Q: Can Dimagrir affect my mood or emotional state?

Official regulatory documents list adverse effects that affect the Psychiatric System. Documented reactions include states such as nervousness, anxiety, and hallucinations.


Q: Is Dimagrir the same as other weight-management drugs I've heard about?

The active ingredient in Dimagrir, Mazindol, is classified pharmacologically as a tricyclic non-amphetamine anorexiant. This classification signifies that its chemical structure is distinct from classic stimulant-based weight management medications.


Q: Are the common side effects of Dimagrir generally mild?

Safety data from the clinical program indicates that common adverse events experienced by participants were typically mild-to-moderate in severity. Clinical studies noted that these effects tended to decrease in frequency and severity with continued treatment.


Q: How long does Dimagrir stay in the body?

Pharmacokinetic data available in official documents show that the elimination half-life of the active ingredient Mazindol is between 10 and 13 hours. The half-life is the time it takes for half of the drug to be processed by the body.


Q: Is Dimagrir available generically?

The FDA determined that the original brand-name product containing Mazindol was not withdrawn from sale for safety or effectiveness reasons. This determination allows for the regulatory approval of generic versions of the drug if all requirements are met.


Q: What kind of monitoring is usually recommended when taking Dimagrir?

Official product information suggests that monitoring of blood pressure and blood sugar may be necessary due to the drug's documented potential to interact with these profiles. Such monitoring ensures comprehensive patient care during treatment.


Q: Do you have to follow a specific diet while on Dimagrir?

Dimagrir is intended solely as an adjunct (an addition) to a comprehensive, medically supervised weight reduction program. This program is based on caloric restriction, physical activity, and behavior modification, not necessarily a specific type of diet.


Q: What if I forget to take my dose of Dimagrir?

Patient information generally provides guidance stating that if a dose is missed, it may be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped entirely to avoid taking more medicine than is recommended.


Q: Is there a risk of developing tolerance to Dimagrir over time?

Some scientific literature and clinical studies have examined the concept of developing a tolerance to the weight loss effects of the active ingredient over time. The development of tolerance is a factor sometimes considered when evaluating long-term treatment efficacy.


Q: Does taking Dimagrir require regular blood tests?

Official product information does not universally mandate routine blood tests. However, due to the drug’s potential constraints in patients with organ insufficiency and its effect on the glycemic profile, official information indicates that laboratory testing may be part of the recommended monitoring for some patients.


Q: Does Dimagrir require special disposal instructions?

As Dimagrir is classified as a controlled substance, it requires special handling for disposal. It is officially recommended to be disposed of via a drug take-back program and is not recommended to be flushed down the toilet or sink.


Q: Can Dimagrir be used by adolescents?

Official regulatory labeling is clear that the medicine is not indicated or recommended for use in pediatric patients, which includes children and adolescents.


Q: Are the effects of Dimagrir permanent after stopping the drug?

Clinical data suggests that the discontinuation of therapy with Dimagrir may be associated with a gradual return to baseline weight. This indicates that the weight reduction benefits are generally not permanent without sustained lifestyle changes.

How should Dimagrir be stored and disposed of?

The storage and disposal of Dimagrir (Mazindol) must strictly follow the conditions defined in official regulatory labeling to ensure product stability and safety.

Storage Requirements

Requirement Official Regulatory Statement
Storage Temperature Store at controlled room temperature (e.g., 20 C to 25 C) or below 30 C; avoid excessive heat.
Protection Must be protected from light and moisture; keep the container tightly closed.
Packaging Keep the tablets in the original container.
Child Safety The medication must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Dimagrir must be disposed of according to established government guidelines, as it is a controlled substance.

The preferred method is using a drug take-back program or an authorized collection site. If a take-back option is unavailable, the tablets may be disposed of in household trash after being mixed with an unappealing substance (such as dirt) and placed in a sealed container to deter misuse. Dimagrir is not recommended to be flushed.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dimagrir found in:

A-Z Index: